Literature DB >> 26618424

Transient and Persistent Antibodies Against TNF-Inhibitors in IBD.

Casper Steenholdt1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26618424     DOI： 10.1038/ajg.2015.325

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  9 in total

1.  Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease.

Authors:  Casper Steenholdt; Magid Al-khalaf; Jørn Brynskov; Klaus Bendtzen; Ole Ø Thomsen; Mark A Ainsworth
Journal:  Inflamm Bowel Dis       Date:  2012-02-16       Impact factor: 5.325

2.  Kinetics of Antibodies Against Adalimumab Are Not Associated With Poor Outcomes in IBD.

Authors:  S Paul; W Dronne; X Roblin
Journal:  Am J Gastroenterol       Date:  2015-05       Impact factor: 10.864

3.  Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.

Authors:  Casper Steenholdt; Klaus Bendtzen; Jørn Brynskov; Ole Ø Thomsen; Lars K Munck; Lisbet A Christensen; Gitte Pedersen; Jens Kjeldsen; Mark A Ainsworth
Journal:  J Crohns Colitis       Date:  2015-01-09       Impact factor: 9.071

4.  Antibody response to infliximab and its impact on pharmacokinetics can be transient.

Authors:  Niels Vande Casteele; Ann Gils; Sharat Singh; Linda Ohrmund; Scott Hauenstein; Paul Rutgeerts; Séverine Vermeire
Journal:  Am J Gastroenterol       Date:  2013-02-19       Impact factor: 10.864

5.  Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial.

Authors:  Casper Steenholdt; Klaus Bendtzen; Jørn Brynskov; Ole Ø Thomsen; Mark A Ainsworth
Journal:  Am J Gastroenterol       Date:  2014-05-06       Impact factor: 10.864

6.  Time Course and Clinical Implications of Development of Antibodies Against Adalimumab in Patients With Inflammatory Bowel Disease.

Authors:  Casper Steenholdt; Madeline T Frederiksen; Klaus Bendtzen; Mark A Ainsworth; Ole Ø Thomsen; Jørn Brynskov
Journal:  J Clin Gastroenterol       Date:  2016-07       Impact factor: 3.062

7.  The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab.

Authors:  Bella Ungar; Yehuda Chowers; Miri Yavzori; Orit Picard; Ella Fudim; Ofir Har-Noy; Uri Kopylov; Rami Eliakim; Shomron Ben-Horin
Journal:  Gut       Date:  2013-09-16       Impact factor: 23.059

8.  Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.

Authors:  Casper Steenholdt; Jørn Brynskov; Ole Østergaard Thomsen; Lars Kristian Munck; Jan Fallingborg; Lisbet Ambrosius Christensen; Gitte Pedersen; Jens Kjeldsen; Bent Ascanius Jacobsen; Anne Sophie Oxholm; Jakob Kjellberg; Klaus Bendtzen; Mark Andrew Ainsworth
Journal:  Gut       Date:  2013-07-22       Impact factor: 23.059

9.  Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.

Authors:  Shomron Ben-Horin; Matti Waterman; Uri Kopylov; Miri Yavzori; Orit Picard; Ella Fudim; Halim Awadie; Batia Weiss; Yehuda Chowers
Journal:  Clin Gastroenterol Hepatol       Date:  2012-10-24       Impact factor: 11.382
  9 in total
  2 in total

1.  Response to Steenholdt.

Authors:  S Paul; Xavier Roblin
Journal:  Am J Gastroenterol       Date:  2015-11       Impact factor: 10.864

2.  Magnitude of Increased Infliximab Clearance Imposed by Anti-infliximab Antibodies in Crohn's Disease Is Determined by Their Concentration.

Authors:  Helena Edlund; Casper Steenholdt; Mark A Ainsworth; Eva Goebgen; Jørn Brynskov; Ole Ø Thomsen; Wilhelm Huisinga; Charlotte Kloft
Journal:  AAPS J       Date:  2016-10-13       Impact factor: 4.009
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.